Keros Therapeutics, Inc.
KROS
$18.10
$1.277.55%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -21.50% | -91.40% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -21.50% | -91.40% | |||
| Cost of Revenue | -55.13% | -10.69% | |||
| Gross Profit | 79.25% | -115.59% | |||
| SG&A Expenses | -30.07% | 37.96% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -48.87% | -2.06% | |||
| Operating Income | 61.36% | -126.19% | |||
| Income Before Tax | 73.56% | -120.77% | |||
| Income Tax Expenses | 35.91% | -122.12% | |||
| Earnings from Continuing Operations | 76.28% | -120.68% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 76.28% | -120.68% | |||
| EBIT | 61.36% | -126.19% | |||
| EBITDA | 62.00% | -125.89% | |||
| EPS Basic | 76.29% | -120.65% | |||
| Normalized Basic EPS | 73.57% | -120.74% | |||
| EPS Diluted | 76.32% | -120.99% | |||
| Normalized Diluted EPS | 73.57% | -120.98% | |||
| Average Basic Shares Outstanding | 0.03% | 0.13% | |||
| Average Diluted Shares Outstanding | 0.03% | -1.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||